Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID).
Pazukhina E., Andreeva M., Spiridonova E., Bobkova P., Shikhaleva A., El-Taravi Y., Rumyantsev M., Gamirova A., Bairashevskaia A., Petrova P., Baimukhambetova D., Pikuza M., Abdeeva E., Filippova Y., Deunezhewa S., Nekliudov N., Bugaeva P., Bulanov N., Avdeev S., Kapustina V., Guekht A., DunnGalvin A., Comberiati P., Peroni DG., Apfelbacher C., Genuneit J., Reyes LF., Brackel CLH., Fomin V., Svistunov AA., Timashev P., Mazankova L., Miroshina A., Samitova E., Borzakova S., Bondarenko E., Korsunskiy AA., Carson G., Sigfrid L., Scott JT., Greenhawt M., Buonsenso D., Semple MG., Warner JO., Olliaro P., Needham DM., Glybochko P., Butnaru D., Osmanov IM., Munblit D., Sechenov StopCOVID Research Team None.
BACKGROUND: Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors. METHODS: Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge. RESULTS: One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47). CONCLUSIONS: Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.